Trade Names:Allegra-D- Tablets 120 mg pseudoephedrine/60 mg fexofenadine
Competitively antagonizes histamine at the H 1 -receptor site.Pseudoephedrine
Causes vasoconstriction and subsequent shrinkage of nasal mucous membranes by alpha-adrenergic stimulation, promoting nasal drainage.
Relief of symptoms associated with seasonal allergic rhinitis.
Hypersensitivity to any ingredient of the product; patients with narrow-angle glaucoma, urinary retention, severe hypertension, or severe coronary artery disease; MAOI therapy; idiosyncratic reactions to adrenergic agents.
PO 1 tablet (60 mg fexofenadine/120 mg pseudoephedrine) twice daily.
Store tablets at controlled room temperature. Keep container tightly closed.
Because the following interactions may occur with the components of this product, take these interactions into consideration when administering the agents that are listed.Fexofenadine Erythromycin, ketoconazole
Plasma levels of fexofenadine may be increased.Pseudoephedrine MAOIs
Contraindicated in patients taking MAOIs and for 14 days after stopping use of an MAOI.Antihypertensive agents that interfere with sympathetic activity (eg, mecamylamine, methyldopa, reserpine, veratrum alkaloids)
Antihypertensive effect of these agents may be reduced.Digitalis
Increased ectopic pacemaker activity may occur.
May diminish or prevent positive reactions to skin tests.
Palpitations; tachycardia, pressor activity, cardiac arrhythmias, CV collapse (pseudoephedrine).
Headache; insomnia; dizziness; agitation; nervousness; anxiety; excitability, restlessness, weakness, drowsiness, fear, tenseness, hallucinations, seizures (pseudoephedrine).
Nausea; dry mouth; dyspepsia; abdominal pain.
Upper respiratory infection; respiratory difficulties.
Assess for allergy symptoms before and periodically throughout therapy. Monitor pulse and BP periodically during therapy.
Category C .
Excreted in breast milk.
Safety and efficacy not established in children younger than 12 yr of age.
Use lower starting dose, reflecting increased incidence of adverse reactions due to decreased hepatic, renal, or cardiac function and comorbidity.
Use with caution in patients with hyperthyroidism, severe hypertension, diabetes, CV disease, increased IOP, or prostatic hypertrophy.
May cause CNS stimulation with convulsions or CV collapse with accompanying hypotension. Monitor patient for nervousness, dizziness, and insomnia.
Dizziness, drowsiness, dry mouth, giddiness, headache, nausea, vomiting, sweating, thirst, tachycardia, precordial pain, palpitations, difficulty in micturition, muscular weakness and tension, anxiety, restlessness, insomnia, toxic psychosis with delusions and hallucinations, cardiac arrhythmias, circulatory collapse, convulsions, coma, respiratory failure.
Copyright © 2009 Wolters Kluwer Health.